Biomarker results in patients, controls and subgroups
| Parameter | Controls (n=89) | All patients (n=114) | Patients with CHD (n=71) | Patients with CMP (n=43) |
|---|---|---|---|---|
| NT-proBNP (pg/mL) | 66 (23–105)* | 294 (106–893)* | 241 (105–543)* | 408 (141–4758)* |
| MR-proANP (pmol/L) | 40 (28–53)* | 74.1 (47.2–166.7)* | 72.8 (47.7–172.9)* | 76.2 (44.7–162.1)* |
| sST2 (ng/mL) | 17.7 (13.7–28.8)# | 23.6 (14.2–37.3)# | 23.5 (13.7–38.1)# | 26.3 (15.1–37.5)# |
| GDF-15 (pg/mL) | 307 (241–501)† | 405 (283–629)† | 405 (286–591)† | 374 (277–707)† |
| MR-proADM (nmol/L) | 0.34 (0.30–0.40) | 0.37 (0.32–0.48) | 0.37 (0.32–0.45) | 0.37 (0.31–0.51) |
Biomarker results for controls, patients with heart failure as well as subgroups with congenital heart disease (CHD) and cardiomyopathy (CMP). All data are presented as medians with IQR. Groups by Kruskal–Wallis test.
*p<0.001; †p=0.070; #p=0.068.
GDF-15, growth differentiating factor 15; MR-proADM, midregional pro-adrenomedullin; MR-proANP, midregional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B natriuretic peptide; sST2, soluble ST2.